๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C

โœ Scribed by Amit Arora; Leonardo Vargas; Tomasz J. Kuzniar

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
128 KB
Volume
4
Category
Article
ISSN
1553-5592

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

Lung toxicity related to interferon (IFN) alpha typically takes a form of interstitial pneumonitis, granulomatous inflammation, or organizing pneumonia. We report a case of a 52โ€yearโ€old woman, who developed pneumonitis with exudative, lymphocyticโ€predominant pleural effusion following treatment with pegylated IFN alpha and ribavirin for hepatitis C. Her symptoms and lung findings resolved over 3 months of observation without corticosteroid therapy. Journal of Hospital Medicine 2009;4:E45โ€“E46. ยฉ 2009 Society of Hospital Medicine.

๐Ÿ“œ SIMILAR VOLUMES

Pegylated interferon and ribavirin thera
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
โœ F. Legrand-Abravanel; F. Nicot; A. Boulestin; K. Sandres-Saunรฉ; J.P. Vinel; L. A ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB

## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCVโ€4 responds poorly to interferon. Pegylated

Pegylated interferon alpha-2b plus ribav
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues
โœ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Effectiveness of hepatitis C treatment w
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients
โœ Paul Feuerstadt; Ari L. Bunim; Heriberto Garcia; Jordan J. Karlitz; Hatef Massou ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 211 KB ๐Ÿ‘ 2 views

Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal of this study was to assess th

Effectiveness of hepatitis C treatment w
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients
โœ Ezequiel Ridruejo; Raรบl Adrover; Daniel Cocozzella; Marรญa Virgina Reggiardo; Nor ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 495 KB ๐Ÿ‘ 2 views

This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocioยดn Cien-tฤฑยดfica y Tecnoloยดgica).

Retreating chronic hepatitis C with dail
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
โœ Bruce R. Bacon; Mitchell L. Shiffman; Flavia Mendes; Reem Ghalib; Tarek Hassanei ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 244 KB ๐Ÿ‘ 1 views

Up to 50% of patients with chronic hepatitis C fail to respond to initial therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). With unsuccessful viral eradication, these patients remain at risk for developing progression of their liver disease. Retreatment with PEG-IFN/RBV yields sustain